Accurately assessing coronary artery stenosis severity is essential for effective risk stratification in elderly patients with coronary heart disease (CHD). A recent retrospective case-control study investigated the roles of lipoprotein-associated phospholipase A2 (Lp-PLA2) and angiotensin II (Ang II) in this population. Researchers analyzed clinical data from 228 patients, categorizing them based on CHD diagnosis and the degree of arterial narrowing. Specifically, the study aimed to determine if these serum biomarkers could reliably predict the clinical severity of the disease.

The analysis revealed that patients with CHD exhibited significantly higher levels of both Lp-PLA2 and Ang II compared to those without the condition. Furthermore, these biomarkers demonstrated a strong positive correlation with the extent of arterial blockage observed during evaluation. Notably, Lp-PLA2 levels showed a direct relationship with lipid profiles, while both markers correlated with the atherogenic index of plasma (AIP). Consequently, elevated serum levels of these molecules represent independent risk factors for advanced coronary conditions in the geriatric population.

Diagnostic Potential for Coronary Artery Stenosis Severity

Transitioning from traditional risk factors to more specific biomarkers could refine clinical decision-making. The study highlighted that both Lp-PLA2 and Ang II possess significant diagnostic value for identifying moderate-to-severe coronary artery stenosis severity. Interestingly, the combination of these two biomarkers yielded results comparable to the atherogenic index of plasma. Moreover, this combined approach outperformed the diagnostic accuracy of either marker used in isolation. Therefore, clinicians might consider integrated biomarker testing to better assess vascular health and target necessary interventions.

Frequently Asked Questions

What is the clinical significance of Lp-PLA2 in elderly patients?

Lp-PLA2 is a vascular-specific inflammatory enzyme associated with plaque instability. In elderly patients, high levels often indicate a greater risk of severe coronary narrowing and adverse cardiovascular events.

Why is Angiotensin II measured alongside Lp-PLA2?

Angiotensin II acts as a potent vasoconstrictor and pro-inflammatory agent. Measuring both provides a comprehensive view of the physiological and inflammatory factors contributing to the progression of heart disease.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Yao H et al. Correlations of coronary lp-PLA2 and angiotensin II levels with the severity of coronary artery stenosis in elderly patients with coronary heart disease: a retrospective case-control study. Curr Med Res Opin. 2026 Jun 13. doi: 10.1080/03007995.2026.2682011. PMID: 42287111.

Cai A, Zheng D, Qiu R, He W, Mai W. Lipoprotein-associated phospholipase A2 is an independent predictor of coronary artery disease and its severity in Chinese patients. Lipids Health Dis. 2015;14:161. doi:10.1186/s12944-015-0161-4.

Sola S, et al. The role of Lp-PLA2 and biochemistry parameters as potential biomarkers of coronary artery disease in Asian South-Indians. Cardiovasc Diagn Ther. 2015;5(5):377-385.